PARIS, France I January 9, 2025 I Results from the investigational, randomized, open-label IRAKLIA phase 3 study demonstrated that Sarclisa administered at a ...
The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of ...
LONDON, UK & SAN FRANCISCO, CA, USA I January 09, 2025 I Verdiva Bio Limited (“Verdiva” or “the Company”) today announced its launch as a clinical-stage ...
CHICAGO, IL, USA I January 8, 2025 I Xentria, Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet medical ...
BEIJING, China I January 8, 2025 I In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide ...
Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily. SAN DIEGO, CA, USA I January 8, 2025 I Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), ...
PALO ALTO, CA and NEEDHAM, MA, USA and MELBOURNE, Australia I January 08, 2025 I Bitterroot Bio, a leader in developing innovative medicines in the field of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback